BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Abu-Alfa AK. Nephrogenic systemic fibrosis and gadolinium-based contrast agents. Adv Chronic Kidney Dis. 2011;18:188-198. [PMID: 21531325 DOI: 10.1053/j.ackd.2011.03.001] [Cited by in Crossref: 69] [Cited by in F6Publishing: 43] [Article Influence: 6.9] [Reference Citation Analysis]
Number Citing Articles
1 Schieda N, Blaichman JI, Costa AF, Glikstein R, Hurrell C, James M, Jabehdar Maralani P, Shabana W, Tang A, Tsampalieros A, van der Pol CB, Hiremath S. Gadolinium-Based Contrast Agents in Kidney Disease: A Comprehensive Review and Clinical Practice Guideline Issued by the Canadian Association of Radiologists.Can J Kidney Health Dis. 2018;5:2054358118778573. [PMID: 29977584 DOI: 10.1177/2054358118778573] [Cited by in Crossref: 37] [Cited by in F6Publishing: 25] [Article Influence: 12.3] [Reference Citation Analysis]
2 Tsukiashi A, Min KS, Kitayama H, Terasawa H, Yoshinaga S, Takeda M, Lindoy LF, Hayami S. Application of spin-crossover water soluble nanoparticles for use as MRI contrast agents. Sci Rep 2018;8:14911. [PMID: 30297794 DOI: 10.1038/s41598-018-33362-6] [Cited by in Crossref: 12] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
3 Loh KP, Ho D, Chiu GNC, Leong DT, Pastorin G, Chow EK. Clinical Applications of Carbon Nanomaterials in Diagnostics and Therapy. Adv Mater 2018;30:e1802368. [PMID: 30133035 DOI: 10.1002/adma.201802368] [Cited by in Crossref: 66] [Cited by in F6Publishing: 41] [Article Influence: 22.0] [Reference Citation Analysis]
4 Bruno F, DeAguero J, Do C, Lee DY, Tan C, Escobar GP, Wagner B. Overlapping roles of NADPH oxidase 4 for diabetic and gadolinium-based contrast agent-induced systemic fibrosis. Am J Physiol Renal Physiol 2021;320:F617-27. [PMID: 33615889 DOI: 10.1152/ajprenal.00456.2020] [Reference Citation Analysis]
5 Gheuens E, Daelemans R, Mesens S. Dialysability of Gadoteric Acid in Patients With End-Stage Renal Disease Undergoing Hemodialysis: . Investigative Radiology 2014;49:505-8. [DOI: 10.1097/rli.0000000000000045] [Cited by in Crossref: 23] [Cited by in F6Publishing: 4] [Article Influence: 3.3] [Reference Citation Analysis]
6 Pan D, Schmieder AH, Wickline SA, Lanza GM. Manganese-based MRI contrast agents: past, present and future. Tetrahedron 2011;67:8431-44. [PMID: 22043109 DOI: 10.1016/j.tet.2011.07.076] [Cited by in Crossref: 212] [Cited by in F6Publishing: 125] [Article Influence: 21.2] [Reference Citation Analysis]
7 Carrasco Muñoz S, Calles Blanco C, Marcin J, Fernández Álvarez C, Lafuente Martínez J. Contrastes basados en gadolinio utilizados en resonancia magnética. Radiología 2014;56:21-8. [DOI: 10.1016/j.rx.2014.06.005] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.9] [Reference Citation Analysis]
8 Huang H, Yue T, Xu K, Golzarian J, Yu J, Huang J. Fabrication and evaluation of tumor-targeted positive MRI contrast agent based on ultrasmall MnO nanoparticles. Colloids and Surfaces B: Biointerfaces 2015;131:148-54. [DOI: 10.1016/j.colsurfb.2015.04.047] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
9 Periyathambi P, Vedakumari WS, Bojja S, Kumar SB, Sastry TP. Green biosynthesis and characterization of fibrin functionalized iron oxide nanoparticles with MRI sensitivity and increased cellular internalization. Materials Chemistry and Physics 2014;148:1212-20. [DOI: 10.1016/j.matchemphys.2014.09.050] [Cited by in Crossref: 16] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
10 Zhang YL, Yu BL, Ren J, Qu K, Wang K, Qiang YQ, Li CX, Sun XW. EADC Values in Diagnosis of Renal Lesions by 3.0 T Diffusion-Weighted Magnetic Resonance Imaging: Compared with the ADC Values. Appl Magn Reson 2013;44:349-63. [PMID: 23476099 DOI: 10.1007/s00723-012-0376-z] [Cited by in Crossref: 20] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
11 Allouche-arnon H, Wade T, Waldner LF, Miller VN, Gomori JM, Katz-brull R, Mckenzie CA. In vivo magnetic resonance imaging of glucose - initial experience: Hyperpolarized MRI of glucose in vivo. Contrast Media Mol Imaging 2013;8:72-82. [DOI: 10.1002/cmmi.1497] [Cited by in Crossref: 44] [Cited by in F6Publishing: 24] [Article Influence: 4.9] [Reference Citation Analysis]
12 Hanssen O, Erpicum P, Lovinfosse P, Meunier P, Weekers L, Tshibanda L, Krzesinski JM, Hustinx R, Jouret F. Non-invasive approaches in the diagnosis of acute rejection in kidney transplant recipients. Part I. In vivo imaging methods. Clin Kidney J 2017;10:97-105. [PMID: 28643821 DOI: 10.1093/ckj/sfw062] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
13 Idée J, Fretellier N, Robic C, Corot C. The role of gadolinium chelates in the mechanism of nephrogenic systemic fibrosis: A critical update. Critical Reviews in Toxicology 2014;44:895-913. [DOI: 10.3109/10408444.2014.955568] [Cited by in Crossref: 66] [Cited by in F6Publishing: 39] [Article Influence: 9.4] [Reference Citation Analysis]
14 Walker JP, Nosova E, Sigovan M, Rapp J, Grenon MS, Owens CD, Gasper WJ, Saloner DA. Ferumoxytol-enhanced magnetic resonance angiography is a feasible method for the clinical evaluation of lower extremity arterial disease. Ann Vasc Surg 2015;29:63-8. [PMID: 25269682 DOI: 10.1016/j.avsg.2014.09.003] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
15 Schieda N, Maralani PJ, Hurrell C, Tsampalieros AK, Hiremath S. Updated Clinical Practice Guideline on Use of Gadolinium-Based Contrast Agents in Kidney Disease Issued by the Canadian Association of Radiologists. Can Assoc Radiol J 2019;70:226-32. [DOI: 10.1016/j.carj.2019.04.001] [Cited by in Crossref: 33] [Cited by in F6Publishing: 17] [Article Influence: 16.5] [Reference Citation Analysis]
16 Fretellier N, Salhi M, Schroeder J, Siegmund H, Chevalier T, Bruneval P, Jestin-Mayer G, Delaloge F, Factor C, Mayer JF, Fabicki JM, Robic C, Bonnemain B, Idée JM, Corot C. Distribution profile of gadolinium in gadolinium chelate-treated renally-impaired rats: role of pharmaceutical formulation. Eur J Pharm Sci 2015;72:46-56. [PMID: 25736527 DOI: 10.1016/j.ejps.2015.02.016] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
17 Mathur M, Jones JR, Weinreb JC. Gadolinium Deposition and Nephrogenic Systemic Fibrosis: A Radiologist’s Primer. RadioGraphics 2020;40:153-62. [DOI: 10.1148/rg.2020190110] [Cited by in Crossref: 28] [Cited by in F6Publishing: 16] [Article Influence: 28.0] [Reference Citation Analysis]
18 Schieda N, Blaichman JI, Costa AF, Glikstein R, Hurrell C, James M, Jabehdar Maralani P, Shabana W, Tang A, Tsampalieros A, van der Pol C, Hiremath S. Gadolinium-Based Contrast Agents in Kidney Disease: Comprehensive Review and Clinical Practice Guideline Issued by the Canadian Association of Radiologists. Can Assoc Radiol J 2018;69:136-50. [PMID: 29706252 DOI: 10.1016/j.carj.2017.11.002] [Cited by in Crossref: 33] [Cited by in F6Publishing: 24] [Article Influence: 11.0] [Reference Citation Analysis]
19 Chevallier P, Walter A, Garofalo A, Veksler I, Lagueux J, Bégin-colin S, Felder-flesch D, Fortin M. Tailored biological retention and efficient clearance of pegylated ultra-small MnO nanoparticles as positive MRI contrast agents for molecular imaging. J Mater Chem B 2014;2:1779-90. [DOI: 10.1039/c3tb21634a] [Cited by in Crossref: 30] [Cited by in F6Publishing: 3] [Article Influence: 4.3] [Reference Citation Analysis]
20 Arendt CT, Leithner D, Lenga L, Wichmann JL, Albrecht MH, Czwikla R, Varga-szemes A, d’Angelo T, Martin SS, Thalhammer A, Nagel E, Vogl TJ, Gruber-rouh T. Multi-observer comparison study between unenhanced quiescent-interval single-shot magnetic resonance angiography and invasive carbon dioxide angiography in patients with peripheral arterial disease and chronic renal insufficiency. European Journal of Radiology 2018;108:140-6. [DOI: 10.1016/j.ejrad.2018.09.029] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
21 Idée J, Fretellier N, Thurnher M, Bonnemain B, Corot C. Physico-chimie et profil toxicologique d’agents de contraste pour l’imagerie par résonance magnétique, les chélates de gadolinium. Annales Pharmaceutiques Françaises 2015;73:266-76. [DOI: 10.1016/j.pharma.2015.01.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
22 Thomsen HS, Morcos SK, Almén T, Bellin MF, Bertolotto M, Bongartz G, Clement O, Leander P, Heinz-Peer G, Reimer P. Nephrogenic systemic fibrosis and gadolinium-based contrast media: updated ESUR Contrast Medium Safety Committee guidelines. Eur Radiol. 2013;23:307-318. [PMID: 22865271 DOI: 10.1007/s00330-012-2597-9] [Cited by in Crossref: 305] [Cited by in F6Publishing: 195] [Article Influence: 33.9] [Reference Citation Analysis]
23 Nardone B, Saddleton E, Laumann AE, Edwards BJ, Raisch DW, McKoy JM, Belknap SM, Bull C, Haryani A, Cowper SE. Pediatric nephrogenic systemic fibrosis is rarely reported: a RADAR report. Pediatr Radiol. 2014;44:173-180. [PMID: 24057195 DOI: 10.1007/s00247-013-2795-x] [Cited by in Crossref: 56] [Cited by in F6Publishing: 37] [Article Influence: 7.0] [Reference Citation Analysis]
24 Bhargava V, Singh K, Meena P, Sanyal R. Nephrogenic systemic fibrosis: A frivolous entity. World J Nephrol 2021;10:29-36. [PMID: 34136369 DOI: 10.5527/wjn.v10.i3.29] [Reference Citation Analysis]
25 Hemalatha T, Prabu P, Gunadharini DN, Gowthaman MK. Fabrication and characterization of dual acting oleyl chitosan functionalised iron oxide/gold hybrid nanoparticles for MRI and CT imaging. Int J Biol Macromol 2018;112:250-7. [PMID: 29378272 DOI: 10.1016/j.ijbiomac.2018.01.159] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
26 Jaw TS, Chen SH, Wang YM, Hsu JS, Kuo YT, Chiu YY, Tsai KB, Hsieh TJ, Liu GC. Comparison of Gd-Bz-TTDA, Gd-EOB-DTPA, and Gd-BOPTA for dynamic MR imaging of the liver in rat models. Kaohsiung J Med Sci 2012;28:130-7. [PMID: 22385605 DOI: 10.1016/j.kjms.2011.10.017] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
27 Baek AR, Kim H, Park S, Lee GH, Kang HJ, Jung J, Park J, Ryeom H, Kim T, Chang Y. Gadolinium Complex of 1,4,7,10-Tetraazacyclododecane-1,4,7-trisacetic Acid (DO3A)–Ethoxybenzyl (EOB) Conjugate as a New Macrocyclic Hepatobiliary MRI Contrast Agent. J Med Chem 2017;60:4861-8. [DOI: 10.1021/acs.jmedchem.7b00060] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
28 Muniraj T, Jamidar PA, Aslanian HR. Pancreatic cancer: a comprehensive review and update. Dis Mon. 2013;59:368-402. [PMID: 24183261 DOI: 10.1016/j.disamonth.2013.08.001] [Cited by in Crossref: 76] [Cited by in F6Publishing: 67] [Article Influence: 9.5] [Reference Citation Analysis]
29 Edwards BJ, Laumann AE, Nardone B, Miller FH, Restaino J, Raisch DW, McKoy JM, Hammel JA, Bhatt K, Bauer K, Samaras AT, Fisher MJ, Bull C, Saddleton E, Belknap SM, Thomsen HS, Kanal E, Cowper SE, Abu Alfa AK, West DP. Advancing pharmacovigilance through academic-legal collaboration: the case of gadolinium-based contrast agents and nephrogenic systemic fibrosis-a Research on Adverse Drug Events and Reports (RADAR) report. Br J Radiol 2014;87:20140307. [PMID: 25230161 DOI: 10.1259/bjr.20140307] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 3.1] [Reference Citation Analysis]
30 Bauer LM, Situ SF, Griswold MA, Samia AC. Magnetic Particle Imaging Tracers: State-of-the-Art and Future Directions. J Phys Chem Lett 2015;6:2509-17. [PMID: 26266727 DOI: 10.1021/acs.jpclett.5b00610] [Cited by in Crossref: 67] [Cited by in F6Publishing: 41] [Article Influence: 11.2] [Reference Citation Analysis]
31 Fretellier N, Bouzian N, Parmentier N, Bruneval P, Jestin G, Factor C, Mandet C, Daubiné F, Massicot F, Laprévote O, Hollenbeck C, Port M, Idée J, Corot C. Nephrogenic Systemic Fibrosis-Like Effects of Magnetic Resonance Imaging Contrast Agents in Rats with Adenine-Induced Renal Failure. Toxicological Sciences 2013;131:259-70. [DOI: 10.1093/toxsci/kfs274] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
32 Montiel Schneider MG, Martin MJ, Coral DF, Muraca D, Gentili C, Fernández van Raap M, Lassalle VL. Selective contrast agents with potential to the earlier detection of tumors: Insights on synthetic pathways, physicochemical properties and performance in MRI assays. Colloids and Surfaces B: Biointerfaces 2018;170:470-8. [DOI: 10.1016/j.colsurfb.2018.06.044] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
33 Nacif MS, Arai AE, Lima JA, Bluemke DA. Gadolinium-enhanced cardiovascular magnetic resonance: administered dose in relationship to United States Food and Drug Administration (FDA) guidelines. J Cardiovasc Magn Reson 2012;14:18. [PMID: 22376193 DOI: 10.1186/1532-429X-14-18] [Cited by in Crossref: 4] [Cited by in F6Publishing: 10] [Article Influence: 0.4] [Reference Citation Analysis]
34 Nandwana SB, Moreno CC, Osipow MT, Sekhar A, Cox KL. Gadobenate Dimeglumine Administration and Nephrogenic Systemic Fibrosis: Is There a Real Risk in Patients with Impaired Renal Function? Radiology 2015;276:741-7. [DOI: 10.1148/radiol.2015142423] [Cited by in Crossref: 35] [Cited by in F6Publishing: 20] [Article Influence: 5.8] [Reference Citation Analysis]
35 Chen TK, Knicely DH, Grams ME. Chronic Kidney Disease Diagnosis and Management: A Review. JAMA 2019;322:1294-304. [PMID: 31573641 DOI: 10.1001/jama.2019.14745] [Cited by in Crossref: 129] [Cited by in F6Publishing: 76] [Article Influence: 64.5] [Reference Citation Analysis]
36 Kitajima K, Maeda T, Watanabe S, Ueno Y, Sugimura K. Recent topics related to nephrogenic systemic fibrosis associated with gadolinium-based contrast agents. Int J Urol 2012;19:806-11. [PMID: 22571387 DOI: 10.1111/j.1442-2042.2012.03042.x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
37 Bai J, Wang X, Zhang C, Huang J, Müller WEG. Lanthanum-containing bioparticles are associated with the influence of lanthanum on high phosphate mediated bone marrow stromal cells viability. Biometals 2018;31:771-84. [DOI: 10.1007/s10534-018-0121-7] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
38 Montiel Schneider MG, Lassalle VL. Magnetic iron oxide nanoparticles as novel and efficient tools for atherosclerosis diagnosis. Biomed Pharmacother 2017;93:1098-115. [PMID: 28738519 DOI: 10.1016/j.biopha.2017.07.012] [Cited by in Crossref: 18] [Cited by in F6Publishing: 11] [Article Influence: 4.5] [Reference Citation Analysis]
39 Giorgi H, Ammerman J, Briffaux J, Fretellier N, Corot C, Bourrinet P. Non-clinical safety assessment of gadoterate meglumine (Dotarem®) in neonatal and juvenile rats. Regulatory Toxicology and Pharmacology 2015;73:960-70. [DOI: 10.1016/j.yrtph.2015.09.018] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
40 Alabousi M, Davenport MS. Use of Intravenous Gadolinium-based Contrast Media in Patients with Kidney Disease and the Risk of Nephrogenic Systemic Fibrosis: Radiology In Training. Radiology 2021;300:279-84. [PMID: 34060939 DOI: 10.1148/radiol.2021210044] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
41 Fischerova D, Cibula D. Ultrasound in Gynecological Cancer: Is It Time for Re-evaluation of Its Uses? Curr Oncol Rep 2015;17. [DOI: 10.1007/s11912-015-0449-x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
42 Ponrartana S, Moore MM, Chan SS, Victoria T, Dillman JR, Chavhan GB. Safety issues related to intravenous contrast agent use in magnetic resonance imaging. Pediatr Radiol 2021;51:736-47. [PMID: 33871726 DOI: 10.1007/s00247-020-04896-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
43 Felder PS, Keller S, Gasser G. Polymetallic Complexes for Applications as Photosensitisers in Anticancer Photodynamic Therapy. Adv Therap 2020;3:1900139. [DOI: 10.1002/adtp.201900139] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 5.5] [Reference Citation Analysis]